Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation

The Journal of Clinical Investigation
K SugitaC Morimoto

Abstract

One of the major obstacles in allogeneic bone marrow transplantation (allo-BMT) is prolonged T cell dysfunction resulting in a variety of infectious complications in the months to years after hematologic engraftment. We previously showed that immobilized extracellular matrix (ECM) proteins such as fibronectin (FN), the CS-1 domain of FN, or collagen (CO) acted synergistically with immobilized anti-CD3 to induce T cell proliferation. In addition, the comitogenic effect of ECMs could be mimicked by immobilized mAb reactive with a common beta 1 chain (CD29) of very late activating (VLA) antigens which include ECM receptors. Since the interaction of T cells with ECMs appears to play an important role in the process of T cell reconstitution following allo-BMT, we examined the expression of VLA antigens (alpha 1-alpha 6, beta 1) and their functional roles in CD3-mediated T cell proliferation at various times after T cell depleted allo-BMT. VLA beta 1 as well as VLA alpha 4, alpha 5, and alpha 6 expression was lower than normal controls during the first 3 mo after allo-BMT and auto-BMT, whereas these expressions returned to normal levels by 4 mo after allo-BMT and auto-BMT. Although alpha 1 and alpha 2 were not expressed on lymphocyte...Continue Reading

References

Apr 1, 1992·The Journal of Experimental Medicine·Y NojimaC Morimoto
Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M D SchallerJ T Parsons
Jan 1, 1991·Annual Review of Cell Biology·R P Mecham
Jul 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·A WeissT Kadlecek
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·N K Damle, A Aruffo
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·L J KornbergR L Juliano
Jul 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·K UtsumiM Ogata
Aug 2, 1990·Nature·T A Springer
Oct 1, 1990·Immunological Reviews·T D GeppertP E Lipsky
Feb 1, 1990·Immunology Today·C T Weaver, E R Unanue
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C H JuneL E Samelson
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P M Cardarelli, M D Pierschbacher
Jul 28, 1986·The American Journal of Medicine·J D Meyers
Sep 1, 1986·Transplantation·M M Bortin, A A Rimm
Aug 1, 1985·Transplantation·A R ZanderE M Hersh

❮ Previous
Next ❯

Citations

Oct 1, 1995·Current Opinion in Immunology·M Theobald
Jan 28, 1999·Leukemia Research·D Blaise, D Maraninchi
Feb 6, 2003·International Journal of Hematology·Sally Arai, Hans G Klingemann
Apr 23, 2004·Experimental Hematology·Elisabet NadalFrancesco Dazzi
Mar 1, 2012·British Journal of Haematology·Andreas HolbroThomas Daikeler
Aug 1, 1997·Thorax·O M Kon, R M du Bois

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.